

Special Issue

Microtubule-Associated Proteins (MAPs) and Cancers

Message from the Guest Editors

Many cancer-related cellular processes, such as cell division and migration, depend on microtubules and their numerous microtubule-associated proteins (MAPs). Both motor MAPs, such as kinesin and dynein, and structural MAPs, such as tau, stathmin, and EB1, have been linked to cancers. Indeed, MAPs have been shown to be overexpressed in tumors and to modulate anticancer drug activity. They have also been proposed as biomarkers or as potential targets in cancer therapies. This Special Issue will focus on MAPs in cancers, covering both fundamental and clinical aspects of their implication in tumor progression, thus advancing our understanding of mechanisms leading to cancer and paving the way to novel improved cancer therapies.

Guest Editors

Prof. Dr. François Devred

Aix-Marseille Université, Institut de NeuroPhysiopathologie, INP, CNRS, UMR 7051, Faculté de Pharmacie, 13385, Marseille, France

Prof. Dr. Christian Poüs

Inserm UMR-S 1193, Université Paris-Saclay Faculté de Pharmacie, 5 rue J.B. Clément, 92296 Châtenay-Malabry, France

Deadline for manuscript submissions

closed (31 October 2024)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/78981

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)